Natural killer T cells in lipoprotein metabolism and atherosclerosis

Por Getz, Godfrey S, VanderLaan, Paul A, Reardon, Catherine A
Publicado em 2011

Features Associated with Locoregional Spread of Papillary Carcinoma Correlate with Diagnostic Category in The Bethesda System for Reporting Thyroid Cytopathology

Por VanderLaan, Paul A., Marqusee, Ellen, Krane, Jeffrey F.
Publicado em 2012

Lung cancer diagnosis and staging in the minimally invasive age with increasing demands for tissue analysis

Por Folch, Erik, Costa, Daniel B., Wright, Jeffrey, VanderLaan, Paul A.
Publicado no Transl Lung Cancer Res (2015)

VLDL best predicts aortic root atherosclerosis in LDL receptor deficient mice

Por VanderLaan, Paul A., Reardon, Catherine A., Thisted, Ronald A., Getz, Godfrey S.
Publicado em 2009

Mammary analogue secretory carcinoma: Update on a New Diagnosis of Salivary Gland Malignancy

Por Sethi, Roshan, Kozin, Elliott, Remenschneider, Aaron, Meier, Josh, VanderLaan, Paul, Faquin, William, Deschler, Daniel, Frankenthaler, Robert
Publicado no Laryngoscope (2013)

Correlation between classic driver oncogene mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% expression in lung adenocarcinoma

Por Rangachari, Deepa, VanderLaan, Paul A., Shea, Meghan, Le, Xiuning, Huberman, Mark S., Kobayashi, Susumu S., Costa, Daniel B.
Publicado no J Thorac Oncol (2017)

Cases of ALK-rearranged lung cancer with 5-year progression-free survival with crizotinib as initial precision therapy

Por Rangachari, Deepa, Le, Xiuning, Shea, Meghan, Huberman, Mark S., VanderLaan, Paul A., Kobayashi, Susumu S., Costa, Daniel B.
Publicado no J Thorac Oncol (2017)

Software-based risk stratification of pulmonary adenocarcinomas manifesting as pure ground glass nodules on computed tomography

Por Nemec, Ursula, Heidinger, Benedikt H., Anderson, Kevin R., Westmore, Michael S., VanderLaan, Paul A., Bankier, Alexander A.
Publicado no Eur Radiol (2017)

PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non–small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a...

Por Torous, Vanda F., Rangachari, Deepa, Gallant, Benjamin P., Shea, Meghan, Costa, Daniel B., VanderLaan, Paul A.
Publicado no J Am Soc Cytopathol (2018)

Rapidly fatal advanced EGFR-mutated lung cancers and the need for rapid tumor genotyping in clinical practice

Por Rangachari, Deepa, Drake, Lauren, Huberman, Mark S., McDonald, Danielle C., VanderLaan, Paul A., Folch, Erik, Costa, Daniel B.
Publicado no Cancer Treat Commun (2016)

Characterization of the Natural Killer T-Cell Response in an Adoptive Transfer Model of Atherosclerosis

Por VanderLaan, Paul A., Reardon, Catherine A., Sagiv, Yuval, Blachowicz, Lydia, Lukens, John, Nissenbaum, Michael, Wang, Chyung-Ru, Getz, Godfrey S.
Publicado em 2007

Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation

Por Jorge, Susan E., Schulman, Sol, Freed, Jason A., VanderLaan, Paul A., Rangachari, Deepa, Kobayashi, Susumu S., Huberman, Mark S., Costa, Daniel B.
Publicado no Lung Cancer (2015)

Morphologic characteristics of pulmonary adenocarcinomas manifesting as pure ground-glass nodules on CT

Por Heidinger, Benedikt H., Anderson, Kevin R., Nemec, Ursula, Costa, Daniel B., Gangadharan, Sidhu P., VanderLaan, Paul A., Bankier, Alexander A.
Publicado no J Thorac Dis (2017)

CCAAT/Enhancer Binding Protein β Is Dispensable for Development of Lung Adenocarcinoma

Por Cai, Yi, Hirata, Ayako, Nakayama, Sohei, VanderLaan, Paul A., Levantini, Elena, Yamamoto, Mihoko, Hirai, Hideyo, Wong, Kwok-Kin, Costa, Daniel B., Watanabe, Hideo, Kobayashi, Susumu S.
Publicado no PLoS One (2015)

Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: correlation with clinical outcomes

Por VanderLaan, Paul A., Rangachari, Deepa, Mockus, Susan M., Spotlow, Vanessa, Reddi, Honey V., Malcolm, Joan, Huberman, Mark S., Joseph, Loren J., Kobayashi, Susumu S., Costa, Daniel B.
Publicado no Lung Cancer (2017)

Tumor biomarker testing in non-small-cell lung cancer: a decade of change

Por VanderLaan, Paul A., Rangachari, Deepa, Majid, Adnan, Parikh, Mihir S., Gangadharan, Sidharta P., Kent, Michael S., McDonald, Danielle C., Huberman, Mark S., Kobayashi, Susumu S., Costa, Daniel B.
Publicado no Lung Cancer (2018)

De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: lack of response to EGFR inhibitors

Por Le, Xiuning, Desai, Neelam V., Majid, Adnan, Karp, Rebecca S., Huberman, Mark S., Rangachari, Deepa, Kent, Michael S., Gangadharan, Sidharta P., Folch, Erik, VanderLaan, Paul A., Costa, Daniel B.
Publicado no Lung Cancer (2015)

Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers

Por Rangachari, Deepa, Yamaguchi, Norihiro, VanderLaan, Paul A., Folch, Erik, Mahadevan, Anand, Floyd, Scott R., Uhlmann, Erik J., Wong, Eric T., Dahlberg, Suzanne E., Huberman, Mark S., Costa, Daniel B.
Publicado no Lung Cancer (2015)

Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice

Por Rangachari, Deepa, VanderLaan, Paul A., Le, Xiuning, Folch, Erik, Kent, Michael S., Gangadharan, Sidharta P., Majid, Adnan, Haspel, Richard L., Joseph, Loren J., Huberman, Mark S., Costa, Daniel B.
Publicado no Cancer Treat Commun (2015)

BRIEF REPORT: Adequacy of lymph node transbronchial needle aspirates using convex probe endobronchial ultrasound for multiple tumor genotyping techniques in non-small-cell lung can...

Por Folch, Erik, Yamaguchi, Norihiro, VanderLaan, Paul A., Kocher, Olivier N., Boucher, David H., Goldstein, Michael A., Huberman, Mark S., Kent, Michael S., Gangadharan, Sidharta P., Costa, Daniel B., Majid, Adnan
Publicado em 2013